Akebia Therapeutics, Inc.
AKBA
$1.43
$0.010.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.46% | 32.49% | 16.75% | -1.24% | -17.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.46% | 32.49% | 16.75% | -1.24% | -17.70% |
| Cost of Revenue | 60.00% | 44.15% | 10.45% | -0.73% | -36.45% |
| Gross Profit | 45.13% | 30.39% | 18.05% | -1.34% | -12.93% |
| SG&A Expenses | 0.88% | 4.56% | 5.96% | 6.19% | 6.30% |
| Depreciation & Amortization | -- | -75.00% | -50.00% | -25.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.26% | 0.45% | -4.08% | -8.37% | -14.02% |
| Operating Income | 158.22% | 169.29% | 116.23% | 48.48% | -2.17% |
| Income Before Tax | 94.64% | 66.76% | 9.79% | -5.30% | -33.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.30% | 65.42% | 9.79% | -5.30% | -33.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.30% | 65.42% | 9.79% | -5.30% | -33.68% |
| EBIT | 158.22% | 169.29% | 116.23% | 48.48% | -2.17% |
| EBITDA | 461.70% | 491.18% | 376.03% | 162.46% | -16.55% |
| EPS Basic | 94.76% | 65.85% | 14.67% | 3.07% | -17.67% |
| Normalized Basic EPS | 99.79% | 74.24% | 17.80% | 5.88% | -13.53% |
| EPS Diluted | 93.83% | 65.35% | 11.58% | 0.36% | -21.40% |
| Normalized Diluted EPS | 99.47% | 73.77% | 17.37% | 5.49% | -13.53% |
| Average Basic Shares Outstanding | 21.87% | 20.45% | 16.93% | 13.54% | 12.52% |
| Average Diluted Shares Outstanding | 24.74% | 23.33% | 18.69% | 14.25% | 12.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |